Navigawaldenstrom Macroglobulinemia By Key Players Overview (Baxter International Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Janssen Pharmaceutica NV (Johnson & Johnson), Merck & Co Inc., Hospira (Pfizer Inc.), etc.)

Waldenstrom macroglobulinemia Market: Overview

Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum, which leads to increased serum viscosity, and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to excess amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to symptoms. In the last few years, medical science has made much progress and a number of new treatments for this type of cancer have been introduced. However, very few studies have been done to compare the treatment options and thus, discover the best available option. Hence, there is no single treatment available that works for all patients. Symptomatic Waldenstrom macroglobulinemia patients are kept under observation and do not receive any treatment until symptoms show up. Patients showing symptoms, such as anemia, hyperviscosity, cold-agglutinin disease, amyloidosis, peripheral neuropathy, etc., are considered for the treatment. Patients that show symptomatic hyperviscosity receive plasmapheresis along with rituximab treatment. In most cases of Waldenstrom macroglobulinemia, combination therapy with chemo and immunotherapy is recommended. Patients with this type of cancer may require stem cell transplantation during the latter stage. Hence, standard chemotherapy agents, such as chlorambucil, bendamustine, cladribine or fludarabine, etc., are not prescribed as first line therapy as they may affect the stem cells. 

Get Free Exclusive Sample Copy of This Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2580

Waldenstrom macroglobulinemia Market: Drivers and Restraints

Improving treatment options and diagnosis rate are the major factors expected to drive the growth of the Waldenstrom macroglobulinemia treatment market over the forecast period. Researchers have found that targeted therapy agents, such as Velcade and Kyprolis, show improved treatment outcomes. Increased treatment seeking rate is another important factor driving the growth of the global Waldenstrom macroglobulinemia treatment market. However, lack of a single standard treatment for all patients and disease complexity are the major factors limiting the growth of global Waldenstrom macroglobulinemia treatment market. High cost of therapy and side effects are some other factors that can hamper the treatment seeking rates and in turn, affect the global market growth. 

Waldenstrom macroglobulinemia Market: Overview

The global market for Waldenstrom macroglobulinemia is expected to witness moderate growth over the forecast period. The targeted therapy segment is expected to witness considerable growth during the forecast period due to increased adoption rate of Waldenstrom macroglobulinemia targeted therapy drugs. Hospitals are the preferred distribution channel for due to requirement of skilled professionals for planning of Waldenstrom macroglobulinemia treatment. Besides, other therapies, such as stem cell transplantation, require highly advanced medical infrastructure. Majority of these treatments are covered under medical part B and hence, hospitals are a preferred distribution channel for Waldenstrom macroglobulinemia treatments.

Waldenstrom macroglobulinemia Market: Regional Outlook

Geographically, the global Waldenstrom macroglobulinemia market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is expected to be the dominant market in the global Waldenstrom macroglobulinemia market owing to high prevalence of the disease and better availability of medical resources in the region. The Waldenstrom macroglobulinemia market in Asia Pacific excluding Japan is expected to grow at a slow rate. Europe is expected to hold second largest share in the global Waldenstrom macroglobulinemia market throughout the forecast period. 

Ask For Customized Report @ https://www.factmr.com/connectus/sample?flag=RC&rep_id=2580

Waldenstrom macroglobulinemia Market: Key Players

Some of the players identified in the global include Baxter International Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Janssen Pharmaceutica NV (Johnson & Johnson), Merck & Co Inc., Hospira (Pfizer Inc.), Takeda Pharmaceutical Company Limited., Amgen Inc., Novartis AG and (Genentech) F. Hoffman-La Roche AG, among others. 

For more information on this report, please visit:https://www.factmr.com/report/2580/navigawaldenstrom-macroglobulinemia-market

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Follow Us on Linkedin: www.linkedin.com/company/factmr/

This release was published on openPR.